Skip to main
RMD

ResMed (RMD) Stock Forecast & Price Target

ResMed (RMD) Analyst Ratings

Based on 11 analyst ratings
Hold
Strong Buy 9%
Buy 27%
Hold 64%
Sell 0%
Strong Sell 0%

Bulls say

ResMed is a strong investment opportunity due to its positive revenue outlook supported by an ageing population and increasing prevalence of obesity. The company's focus on digital health and clinical data sets it apart from its competitors, and its recent acquisition of MatrixCare will likely further enhance its offerings. Risks to the company include potential competition and potential disruptions in the sleep market from GLP-1 drugs. EPS increases and strong performances in key areas further strengthen the positive outlook.

Bears say

ResMed is facing uncertainty in its growth opportunities due to the impact on the diagnosis and treatment of sleep apnea from GLP-1 drugs, and the recent sale of its MatrixCare business for $490m suggests a lack of confidence in future growth prospects from management. The company has a highly defensive revenue stream, but potential risks include increased competition, lack of technological innovation, and updates on GLP-1 trials. Overall, the uncertainty surrounding GLP-1 impacts and recent developments suggest a cautious outlook for ResMed's stock.

ResMed (RMD) has been analyzed by 11 analysts, with a consensus rating of Hold. 9% of analysts recommend a Strong Buy, 27% recommend Buy, 64% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ResMed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ResMed (RMD) Forecast

Analysts have given ResMed (RMD) a Hold based on their latest research and market trends.

According to 11 analysts, ResMed (RMD) has a Hold consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $256.09, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $256.09, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ResMed (RMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.